Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela, R. Jake Jacobs, Oscar Arteaga, Maria S. Navarrete, Allen S. Meyerhoff, Bruce L. Innis

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.
Original languageAmerican English
Pages (from-to)4110-4119
Number of pages10
Issue number32
StatePublished - 14 Jul 2005
Externally publishedYes


  • Cost and cost analysis
  • Hepatitis A
  • Vaccination

Fingerprint Dive into the research topics of 'Cost-effectiveness of universal childhood hepatitis A vaccination in Chile'. Together they form a unique fingerprint.

Cite this